Abstract
We study the effects of two mechanisms which increase the efficacy of contact-tracing applications (CTAs) such as the mobile phone contact-tracing applications that have been used during the COVID-19 epidemic. The first mechanism is the introduction of user referrals. We compare four scenarios for the uptake of CTAs — (1) the p% of individuals that use the CTA are chosen randomly, (2) a smaller initial set of randomly-chosen users each refer a contact to use the CTA, achieving p% in total, (3) a small initial set of randomly-chosen users each refer around half of their contacts to use the CTA, achieving p% in total, and (4) for comparison, an idealised scenario in which the p% of the population that uses the CTA is the p% with the most contacts. Using agent-based epidemiological models incorporating a geometric space, we find that, even when the uptake percentage p% is small, CTAs are an effective tool for mitigating the spread of the epidemic in all scenarios. Moreover, user referrals significantly improve efficacy. In addition, it turns out that user referrals reduce the quarantine load. The second mechanism for increasing the efficacy of CTAs is tuning the severity of quarantine measures. Our modelling shows that using CTAs with mild quarantine measures is effective in reducing the maximum hospital load and the number of people who become ill, but leads to a relatively high quarantine load, which may cause economic disruption. Fortunately, under stricter quarantine measures, the advantages are maintained but the quarantine load is reduced. Our models incorporate geometric inhomogeneous random graphs to study the effects of the presence of super-spreaders and of the absence of long-distant contacts (e.g., through travel restrictions) on our conclusions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of Joost Jorritsma and Júlia Komájthy is partly supported by the Netherlands Organisation for Scientific Research (NWO) through grant NWO 613.009.122. There was no additional external funding received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We clarified our our wording throughout the paper and added several remarks. All figures are revised and display the spread of our results over several runs (instead of just the median). We have added references to existing literature.
Data Availability
The software can be obtained from the authors. The data is available via 10.5281/zenodo.4601163.
